Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	dopamine neurotransmitter receptor activity, coupled via Gi/Go	DRD2 DRD3	3.80e-06	3	23	2	GO:0001591
GeneOntologyMolecularFunction	dopamine neurotransmitter receptor activity	DRD2 DRD3	1.27e-05	5	23	2	GO:0004952
GeneOntologyMolecularFunction	catecholamine binding	DRD2 ADRA2B	9.82e-05	13	23	2	GO:1901338
GeneOntologyBiologicalProcess	negative regulation of synaptic transmission, glutamatergic	MYO5A DRD2 DRD3	3.44e-07	13	23	3	GO:0051967
GeneOntologyBiologicalProcess	locomotion involved in locomotory behavior	MYO5A DRD2 DRD3	8.15e-07	17	23	3	GO:0031987
GeneOntologyBiologicalProcess	regulation of catecholamine secretion	MYO5A DRD2 DRD3 ADRA2B	8.59e-07	67	23	4	GO:0050433
GeneOntologyBiologicalProcess	catecholamine secretion	MYO5A DRD2 DRD3 ADRA2B	1.67e-06	79	23	4	GO:0050432
GeneOntologyBiologicalProcess	negative regulation of catecholamine secretion	MYO5A DRD2 ADRA2B	2.11e-06	23	23	3	GO:0033604
GeneOntologyBiologicalProcess	adenylate cyclase-activating adrenergic receptor signaling pathway	DRD2 DRD3 ADRA2B	2.74e-06	25	23	3	GO:0071880
GeneOntologyBiologicalProcess	regulation of synaptic transmission, glutamatergic	MYO5A NLGN2 DRD2 DRD3	3.08e-06	92	23	4	GO:0051966
GeneOntologyBiologicalProcess	catecholamine transport	MYO5A DRD2 DRD3 ADRA2B	3.65e-06	96	23	4	GO:0051937
GeneOntologyBiologicalProcess	regulation of dopamine secretion	MYO5A DRD2 DRD3	7.09e-06	34	23	3	GO:0014059
GeneOntologyBiologicalProcess	negative regulation of dopamine receptor signaling pathway	DRD2 DRD3	7.13e-06	4	23	2	GO:0060160
GeneOntologyBiologicalProcess	monoamine transport	MYO5A DRD2 DRD3 ADRA2B	7.74e-06	116	23	4	GO:0015844
GeneOntologyBiologicalProcess	adrenergic receptor signaling pathway	DRD2 DRD3 ADRA2B	7.74e-06	35	23	3	GO:0071875
GeneOntologyBiologicalProcess	regulation of amine transport	MYO5A DRD2 DRD3 ADRA2B	1.04e-05	125	23	4	GO:0051952
GeneOntologyBiologicalProcess	dopamine secretion	MYO5A DRD2 DRD3	1.26e-05	41	23	3	GO:0014046
GeneOntologyBiologicalProcess	synaptic transmission, glutamatergic	MYO5A NLGN2 DRD2 DRD3	1.29e-05	132	23	4	GO:0035249
GeneOntologyBiologicalProcess	negative regulation of amine transport	MYO5A DRD2 ADRA2B	1.45e-05	43	23	3	GO:0051953
GeneOntologyBiologicalProcess	amine transport	MYO5A DRD2 DRD3 ADRA2B	1.50e-05	137	23	4	GO:0015837
GeneOntologyBiologicalProcess	adenylate cyclase-inhibiting dopamine receptor signaling pathway	DRD2 DRD3	1.78e-05	6	23	2	GO:0007195
GeneOntologyBiologicalProcess	negative regulation of dopamine secretion	MYO5A DRD2	2.49e-05	7	23	2	GO:0033602
GeneOntologyBiologicalProcess	dopamine metabolic process	MYO5A DRD2 DRD3	2.74e-05	53	23	3	GO:0042417
GeneOntologyBiologicalProcess	regulation of locomotion involved in locomotory behavior	DRD2 DRD3	3.32e-05	8	23	2	GO:0090325
GeneOntologyBiologicalProcess	dopamine transport	MYO5A DRD2 DRD3	3.41e-05	57	23	3	GO:0015872
GeneOntologyBiologicalProcess	response to amine	JAK2 DRD2 DRD3	3.59e-05	58	23	3	GO:0014075
GeneOntologyBiologicalProcess	phospholipase C-activating dopamine receptor signaling pathway	DRD2 DRD3	4.26e-05	9	23	2	GO:0060158
GeneOntologyBiologicalProcess	regulation of dopamine uptake involved in synaptic transmission	DRD2 DRD3	4.26e-05	9	23	2	GO:0051584
GeneOntologyBiologicalProcess	regulation of catecholamine uptake involved in synaptic transmission	DRD2 DRD3	4.26e-05	9	23	2	GO:0051940
GeneOntologyBiologicalProcess	signal release	MYO5A JAK2 NLGN2 DRD2 DRD3 ADRA2B	6.27e-05	653	23	6	GO:0023061
GeneOntologyBiologicalProcess	regulation of dopamine receptor signaling pathway	DRD2 DRD3	6.50e-05	11	23	2	GO:0060159
GeneOntologyBiologicalProcess	catechol-containing compound metabolic process	MYO5A DRD2 DRD3	7.46e-05	74	23	3	GO:0009712
GeneOntologyBiologicalProcess	catecholamine metabolic process	MYO5A DRD2 DRD3	7.46e-05	74	23	3	GO:0006584
GeneOntologyBiologicalProcess	response to histamine	DRD2 DRD3	7.80e-05	12	23	2	GO:0034776
GeneOntologyBiologicalProcess	negative regulation of secretion by cell	MYO5A DRD2 DRD3 ADRA2B	8.55e-05	214	23	4	GO:1903531
GeneOntologyBiologicalProcess	dopamine uptake involved in synaptic transmission	DRD2 DRD3	9.21e-05	13	23	2	GO:0051583
GeneOntologyBiologicalProcess	catecholamine uptake involved in synaptic transmission	DRD2 DRD3	9.21e-05	13	23	2	GO:0051934
GeneOntologyBiologicalProcess	negative regulation of synaptic transmission	MYO5A DRD2 DRD3	9.41e-05	80	23	3	GO:0050805
GeneOntologyBiologicalProcess	neuromuscular process	MYO5A NLGN2 DRD2 DRD3	1.04e-04	225	23	4	GO:0050905
GeneOntologyBiologicalProcess	response to morphine	DRD2 DRD3	1.24e-04	15	23	2	GO:0043278
GeneOntologyBiologicalProcess	regulation of secretion by cell	MYO5A JAK2 NLGN2 DRD2 DRD3 ADRA2B	1.25e-04	740	23	6	GO:1903530
GeneOntologyBiologicalProcess	negative regulation of secretion	MYO5A DRD2 DRD3 ADRA2B	1.31e-04	239	23	4	GO:0051048
GeneOntologyBiologicalProcess	response to isoquinoline alkaloid	DRD2 DRD3	1.41e-04	16	23	2	GO:0014072
GeneOntologyBiologicalProcess	regulation of calcium ion transmembrane transporter activity	MYO5A DRD2 DRD3	1.43e-04	92	23	3	GO:1901019
GeneOntologyBiologicalProcess	protein secretion	MYO5A JAK2 NLGN2 DRD2 DRD3	1.59e-04	480	23	5	GO:0009306
GeneOntologyBiologicalProcess	establishment of protein localization to extracellular region	MYO5A JAK2 NLGN2 DRD2 DRD3	1.64e-04	483	23	5	GO:0035592
GeneOntologyBiologicalProcess	regulation of monoatomic ion transmembrane transporter activity	MYO5A NLGN2 DRD2 DRD3	1.70e-04	256	23	4	GO:0032412
GeneOntologyBiologicalProcess	protein localization to extracellular region	MYO5A JAK2 NLGN2 DRD2 DRD3	1.75e-04	490	23	5	GO:0071692
GeneOntologyBiologicalProcess	negative regulation of adenylate cyclase activity	DRD2 DRD3	1.80e-04	18	23	2	GO:0007194
GeneOntologyBiologicalProcess	regulation of secretion	MYO5A JAK2 NLGN2 DRD2 DRD3 ADRA2B	1.93e-04	801	23	6	GO:0051046
GeneOntologyBiologicalProcess	regulation of transmembrane transporter activity	MYO5A NLGN2 DRD2 DRD3	1.97e-04	266	23	4	GO:0022898
GeneOntologyBiologicalProcess	negative regulation of cyclase activity	DRD2 DRD3	2.01e-04	19	23	2	GO:0031280
GeneOntologyBiologicalProcess	insulin secretion	MYO5A JAK2 NLGN2 DRD2	2.21e-04	274	23	4	GO:0030073
GeneOntologyBiologicalProcess	prepulse inhibition	DRD2 DRD3	2.23e-04	20	23	2	GO:0060134
GeneOntologyBiologicalProcess	dopamine uptake	DRD2 DRD3	2.23e-04	20	23	2	GO:0090494
GeneOntologyBiologicalProcess	G protein-coupled receptor internalization	DRD2 DRD3	2.47e-04	21	23	2	GO:0002031
GeneOntologyBiologicalProcess	negative regulation of voltage-gated calcium channel activity	DRD2 DRD3	2.47e-04	21	23	2	GO:1901386
GeneOntologyBiologicalProcess	catecholamine uptake	DRD2 DRD3	2.47e-04	21	23	2	GO:0090493
GeneOntologyBiologicalProcess	locomotory behavior	MYO5A NLGN2 DRD2 DRD3	2.53e-04	284	23	4	GO:0007626
GeneOntologyBiologicalProcess	negative regulation of lyase activity	DRD2 DRD3	2.71e-04	22	23	2	GO:0051350
GeneOntologyBiologicalProcess	regulation of transporter activity	MYO5A NLGN2 DRD2 DRD3	3.08e-04	299	23	4	GO:0032409
GeneOntologyBiologicalProcess	biogenic amine metabolic process	MYO5A DRD2 DRD3	3.20e-04	121	23	3	GO:0006576
GeneOntologyBiologicalProcess	behavioral response to cocaine	DRD2 DRD3	3.23e-04	24	23	2	GO:0048148
GeneOntologyBiologicalProcess	regulation of neurotransmitter uptake	DRD2 DRD3	3.23e-04	24	23	2	GO:0051580
GeneOntologyBiologicalProcess	negative regulation of cytosolic calcium ion concentration	DRD2 DRD3	3.51e-04	25	23	2	GO:0051481
GeneOntologyBiologicalProcess	chromatin organization	SHPRH JAK2 HAT1 TFPT KANSL2 HJURP	3.53e-04	896	23	6	GO:0006325
GeneOntologyBiologicalProcess	regulation of signaling receptor activity	JAK2 NLGN2 ADRA2B	4.04e-04	131	23	3	GO:0010469
GeneOntologyBiologicalProcess	peptide hormone secretion	MYO5A JAK2 NLGN2 DRD2	4.69e-04	334	23	4	GO:0030072
GeneOntologyBiologicalProcess	regulation of cation channel activity	MYO5A DRD2 DRD3	4.70e-04	138	23	3	GO:2001257
GeneOntologyBiologicalProcess	phenol-containing compound metabolic process	MYO5A DRD2 DRD3	5.11e-04	142	23	3	GO:0018958
GeneOntologyBiologicalProcess	peptide secretion	MYO5A JAK2 NLGN2 DRD2	5.18e-04	343	23	4	GO:0002790
GeneOntologyBiologicalProcess	regulation of circadian sleep/wake cycle, sleep	DRD2 DRD3	5.42e-04	31	23	2	GO:0045187
GeneOntologyBiologicalProcess	desensitization of G protein-coupled receptor signaling pathway	DRD2 DRD3	5.42e-04	31	23	2	GO:0002029
GeneOntologyBiologicalProcess	regulation of protein secretion	JAK2 NLGN2 DRD2 DRD3	5.59e-04	350	23	4	GO:0050708
GeneOntologyBiologicalProcess	amine metabolic process	MYO5A DRD2 DRD3	5.77e-04	148	23	3	GO:0009308
GeneOntologyBiologicalProcess	negative adaptation of signaling pathway	DRD2 DRD3	5.78e-04	32	23	2	GO:0022401
GeneOntologyBiologicalProcess	adaptation of signaling pathway	DRD2 DRD3	5.78e-04	32	23	2	GO:0023058
GeneOntologyBiologicalProcess	peptide transport	MYO5A JAK2 NLGN2 DRD2	5.90e-04	355	23	4	GO:0015833
GeneOntologyBiologicalProcess	organic hydroxy compound transport	MYO5A DRD2 DRD3 ADRA2B	6.09e-04	358	23	4	GO:0015850
GeneOntologyBiologicalProcess	positive regulation of signaling receptor activity	JAK2 ADRA2B	6.15e-04	33	23	2	GO:2000273
GeneOntologyBiologicalProcess	circadian sleep/wake cycle, sleep	DRD2 DRD3	6.15e-04	33	23	2	GO:0050802
GeneOntologyBiologicalProcess	protein-DNA complex organization	SHPRH JAK2 HAT1 TFPT KANSL2 HJURP	6.31e-04	999	23	6	GO:0071824
GeneOntologyBiologicalProcess	positive regulation of peptide hormone secretion	JAK2 NLGN2 DRD2	6.85e-04	157	23	3	GO:0090277
GeneOntologyBiologicalProcess	regulation of circadian sleep/wake cycle	DRD2 DRD3	6.92e-04	35	23	2	GO:0042749
GeneOntologyBiologicalProcess	synaptic transmission, dopaminergic	DRD2 DRD3	6.92e-04	35	23	2	GO:0001963
GeneOntologyBiologicalProcess	modulation of chemical synaptic transmission	MYO5A JAK2 NLGN2 DRD2 DRD3	7.03e-04	663	23	5	GO:0050804
GeneOntologyBiologicalProcess	regulation of trans-synaptic signaling	MYO5A JAK2 NLGN2 DRD2 DRD3	7.08e-04	664	23	5	GO:0099177
GeneOntologyBiologicalProcess	circadian sleep/wake cycle process	DRD2 DRD3	7.32e-04	36	23	2	GO:0022410
GeneOntologyBiologicalProcess	arachidonate transport	DRD2 DRD3	7.32e-04	36	23	2	GO:1903963
GeneOntologyBiologicalProcess	arachidonate secretion	DRD2 DRD3	7.32e-04	36	23	2	GO:0050482
GeneOntologyBiologicalProcess	positive regulation of peptide secretion	JAK2 NLGN2 DRD2	7.37e-04	161	23	3	GO:0002793
GeneOntologyBiologicalProcess	neurotransmitter reuptake	DRD2 DRD3	8.16e-04	38	23	2	GO:0098810
GeneOntologyBiologicalProcess	regulation of voltage-gated calcium channel activity	DRD2 DRD3	8.16e-04	38	23	2	GO:1901385
GeneOntologyBiologicalProcess	peroxisome organization	PEX16 PJVK	8.60e-04	39	23	2	GO:0007031
GeneOntologyBiologicalProcess	secretion by cell	MYO5A JAK2 NLGN2 DRD2 DRD3 ADRA2B	8.79e-04	1064	23	6	GO:0032940
GeneOntologyBiologicalProcess	response to amphetamine	DRD2 DRD3	9.04e-04	40	23	2	GO:0001975
GeneOntologyBiologicalProcess	sleep	DRD2 DRD3	9.04e-04	40	23	2	GO:0030431
GeneOntologyBiologicalProcess	negative regulation of calcium ion transmembrane transporter activity	DRD2 DRD3	9.50e-04	41	23	2	GO:1901020
GeneOntologyBiologicalProcess	startle response	DRD2 DRD3	9.50e-04	41	23	2	GO:0001964
GeneOntologyBiologicalProcess	circadian sleep/wake cycle	DRD2 DRD3	1.04e-03	43	23	2	GO:0042745
GeneOntologyBiologicalProcess	positive regulation of G protein-coupled receptor signaling pathway	DRD2 DRD3	1.09e-03	44	23	2	GO:0045745
GeneOntologyBiologicalProcess	G protein-coupled dopamine receptor signaling pathway	DRD2 DRD3	1.09e-03	44	23	2	GO:0007212
GeneOntologyBiologicalProcess	hormone secretion	MYO5A JAK2 NLGN2 DRD2	1.10e-03	420	23	4	GO:0046879
GeneOntologyCellularComponent	dopaminergic synapse	NLGN2 DRD2 DRD3	1.77e-06	22	23	3	GO:0098691
GeneOntologyCellularComponent	actin cytoskeleton	MYO5A TFPT KANSL2 PJVK NCOA5	3.48e-04	576	23	5	GO:0015629
GeneOntologyCellularComponent	microbody	PEX16 MYO5A PJVK	7.22e-04	162	23	3	GO:0042579
GeneOntologyCellularComponent	peroxisome	PEX16 MYO5A PJVK	7.22e-04	162	23	3	GO:0005777
GeneOntologyCellularComponent	GABA-ergic synapse	NLGN2 DRD2 DRD3	7.48e-04	164	23	3	GO:0098982
GeneOntologyCellularComponent	endosome lumen	JAK2 AP4B1	1.02e-03	43	23	2	GO:0031904
GeneOntologyCellularComponent	microbody membrane	PEX16 PJVK	2.60e-03	69	23	2	GO:0031903
GeneOntologyCellularComponent	peroxisomal membrane	PEX16 PJVK	2.60e-03	69	23	2	GO:0005778
GeneOntologyCellularComponent	postsynapse	MYO5A JAK2 NLGN2 DRD2 DRD3	4.38e-03	1018	23	5	GO:0098794
GeneOntologyCellularComponent	chromatin	SHPRH JAK2 HAT1 TFEC TFPT KANSL2	4.42e-03	1480	23	6	GO:0000785
MousePheno	stereotypic behavior	MYO5A DRD2 DRD3 PJVK	8.41e-05	214	16	4	MP:0001408
MousePheno	decreased startle reflex	NLGN2 DRD2 DRD3 PJVK	1.00e-04	224	16	4	MP:0001489
MousePheno	decreased alcohol consumption	DRD2 DRD3	1.46e-04	16	16	2	MP:0003546
Domain	Dopamine_rcpt	DRD2 DRD3	1.32e-05	5	22	2	IPR000929
Domain	Anticodon-bd	IMP4 NCOA5	1.20e-04	14	22	2	IPR004154
Domain	7TM_GPCR_Srsx	DRD2 DRD3 ADRA2B	2.97e-04	112	22	3	SM01381
Domain	IQ	MYO5A SCN9A	3.13e-03	71	22	2	PF00612
Domain	IQ	MYO5A SCN9A	4.06e-03	81	22	2	SM00015
Domain	IQ_motif_EF-hand-BS	MYO5A SCN9A	4.98e-03	90	22	2	IPR000048
Domain	IQ	MYO5A SCN9A	5.31e-03	93	22	2	PS50096
Pathway	WP_MONOAMINE_GPCRS	DRD2 DRD3 ADRA2B	1.07e-05	31	20	3	MM15871
Pathway	WP_MONOAMINE_GPCRS	DRD2 DRD3 ADRA2B	1.30e-05	33	20	3	M39585
Pathway	REACTOME_DOPAMINE_RECEPTORS	DRD2 DRD3	1.91e-05	5	20	2	M27301
Pathway	REACTOME_DOPAMINE_RECEPTORS	DRD2 DRD3	1.91e-05	5	20	2	MM15007
Pathway	REACTOME_AMINE_LIGAND_BINDING_RECEPTORS	DRD2 DRD3 ADRA2B	2.71e-05	42	20	3	M5868
Pathway	REACTOME_AMINE_LIGAND_BINDING_RECEPTORS	DRD2 DRD3 ADRA2B	2.71e-05	42	20	3	MM14971
Pathway	WP_NICOTINE_EFFECT_ON_DOPAMINERGIC_NEURONS	DRD2 DRD3	3.95e-04	21	20	2	M39343
Pubmed	Striatal dopamine D2/3 receptor availability increases after long-term bariatric surgery-induced weight loss.	DRD2 DRD3	4.18e-07	2	23	2	27184782
Pubmed	N-linked Glycosylation on the N-terminus of the dopamine D2 and D3 receptors determines receptor association with specific microdomains in the plasma membrane.	DRD2 DRD3	4.18e-07	2	23	2	25289757
Pubmed	Dopamine receptor D2 and D3 gene variants are not associated with the antidepressant effect of total sleep deprivation in bipolar depression.	DRD2 DRD3	4.18e-07	2	23	2	12834818
Pubmed	Mapping the landscape of human dopamine D2/3 receptors with [11C]raclopride.	DRD2 DRD3	4.18e-07	2	23	2	31444615
Pubmed	Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.	DRD2 DRD3	4.18e-07	2	23	2	23154100
Pubmed	Homology modeling of dopamine D2 and D3 receptors: molecular dynamics refinement and docking evaluation.	DRD2 DRD3	4.18e-07	2	23	2	22970199
Pubmed	Association of novelty seeking scores and striatal dopamine D₂/D₃ receptor availability of healthy volunteers: single photon emission computed tomography with ¹²³i-iodobenzamide.	DRD2 DRD3	4.18e-07	2	23	2	20970071
Pubmed	Variability in Action Selection Relates to Striatal Dopamine 2/3 Receptor Availability in Humans: A PET Neuroimaging Study Using Reinforcement Learning and Active Inference Models.	DRD2 DRD3	4.18e-07	2	23	2	32083297
Pubmed	Posterior dopamine D2/3 receptors and brain network functional connectivity.	DRD2 DRD3	4.18e-07	2	23	2	28700819
Pubmed	Association study of dopamine D2 and D3 receptor gene polymorphisms with cocaine dependence.	DRD2 DRD3	4.18e-07	2	23	2	16094250
Pubmed	In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study.	DRD2 DRD3	4.18e-07	2	23	2	22234337
Pubmed	Decreased c-fos responses to dopamine D(1) receptor agonist stimulation in mice deficient for D(3) receptors.	DRD2 DRD3	4.18e-07	2	23	2	10506202
Pubmed	DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder.	DRD2 DRD3	4.18e-07	2	23	2	23683269
Pubmed	Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients.	DRD2 DRD3	4.18e-07	2	23	2	12740603
Pubmed	Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).	DRD2 DRD3	4.18e-07	2	23	2	19011428
Pubmed	Palmitoylation on the carboxyl terminus tail is required for the selective regulation of dopamine D2 versus D3 receptors.	DRD2 DRD3	4.18e-07	2	23	2	27349735
Pubmed	Association between DRD2 and DRD3 gene polymorphisms and gastrointestinal symptoms induced by levodopa therapy in Parkinson's disease.	DRD2 DRD3	4.18e-07	2	23	2	27779245
Pubmed	Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors.	DRD2 DRD3	4.18e-07	2	23	2	19302829
Pubmed	Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F]fallypride and voxel-based morphometry study.	DRD2 DRD3	4.18e-07	2	23	2	19457373
Pubmed	No association of dopamine receptor sensitivity in vivo with genetic predisposition for alcoholism and DRD2/DRD3 gene polymorphisms in alcohol dependence.	DRD2 DRD3	4.18e-07	2	23	2	16759339
Pubmed	-141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population.	DRD2 DRD3	4.18e-07	2	23	2	18496209
Pubmed	Mice lacking dopamine D2 and D3 receptors exhibit differential activation of prefrontal cortical neurons during tasks requiring attention.	DRD2 DRD3	4.18e-07	2	23	2	15537671
Pubmed	Signaling pathways leading to phosphorylation of Akt and GSK-3β by activation of cloned human and rat cerebral D₂and D₃ receptors.	DRD2 DRD3	4.18e-07	2	23	2	20952497
Pubmed	G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors.	DRD2 DRD3	4.18e-07	2	23	2	18218829
Pubmed	Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.	DRD2 DRD3	4.18e-07	2	23	2	18410503
Pubmed	Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD.	DRD2 DRD3	4.18e-07	2	23	2	11425949
Pubmed	Cortical dopamine D2/D3 receptors and verbal memory in man.	DRD2 DRD3	4.18e-07	2	23	2	20188195
Pubmed	Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.	DRD2 DRD3	4.18e-07	2	23	2	25511804
Pubmed	Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.	DRD2 DRD3	4.18e-07	2	23	2	21663922
Pubmed	Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.	DRD2 DRD3	4.18e-07	2	23	2	26819282
Pubmed	The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain.	DRD2 DRD3	4.18e-07	2	23	2	8313980
Pubmed	Dopamine D2 receptors preferentially regulate the development of light responses of the inner retina.	DRD2 DRD3	4.18e-07	2	23	2	25393815
Pubmed	The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study.	DRD2 DRD3	4.18e-07	2	23	2	18987627
Pubmed	Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.	DRD2 DRD3	4.18e-07	2	23	2	19396436
Pubmed	Roles of conserved intracellular sequences regions for the proper expression of dopamine D(2) and D(3) receptors.	DRD2 DRD3	4.18e-07	2	23	2	18481021
Pubmed	Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain.	DRD2 DRD3	4.18e-07	2	23	2	32818617
Pubmed	The candidate gene approach in alcoholism: are there gender-specific differences?	DRD2 DRD3	4.18e-07	2	23	2	14628173
Pubmed	The E2.65A mutation disrupts dynamic binding poses of SB269652 at the dopamine D2 and D3 receptors.	DRD2 DRD3	4.18e-07	2	23	2	29337986
Pubmed	Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain.	DRD2 DRD3	4.18e-07	2	23	2	22573693
Pubmed	Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity.	DRD2 DRD3	4.18e-07	2	23	2	24785761
Pubmed	New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion.	DRD2 DRD3	4.18e-07	2	23	2	30626912
Pubmed	Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors.	DRD2 DRD3	4.18e-07	2	23	2	10391470
Pubmed	D2/D3 dopamine receptor binding with [F-18]fallypride correlates of executive function in medication-naïve patients with schizophrenia.	DRD2 DRD3	4.18e-07	2	23	2	28576546
Pubmed	Comparative studies of molecular mechanisms of dopamine D2 and D3 receptors for the activation of extracellular signal-regulated kinase.	DRD2 DRD3	4.18e-07	2	23	2	15102843
Pubmed	DRD3 (dopamine receptor D3) but not DRD2 activates autophagy through MTORC1 inhibition preserving protein synthesis.	DRD2 DRD3	4.18e-07	2	23	2	31538542
Pubmed	Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.	DRD2 DRD3	4.18e-07	2	23	2	19669131
Pubmed	Elevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans.	DRD2 DRD3	4.18e-07	2	23	2	23954846
Pubmed	Striatal dopamine D₂/D₃ receptor binding in pathological gambling is correlated with mood-related impulsivity.	DRD2 DRD3	4.18e-07	2	23	2	22776462
Pubmed	Cigarette Use and Striatal Dopamine D2/3 Receptors: Possible Role in the Link between Smoking and Nicotine Dependence.	DRD2 DRD3	4.18e-07	2	23	2	27634830
Pubmed	Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease.	DRD2 DRD3	4.18e-07	2	23	2	33039854
Pubmed	Exploring personality traits related to dopamine D2/3 receptor availability in striatal subregions of humans.	DRD2 DRD3	4.18e-07	2	23	2	26944295
Pubmed	Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.	DRD2 DRD3	4.18e-07	2	23	2	16959057
Pubmed	Fluorescent ligands for dopamine D2/D3 receptors.	DRD2 DRD3	4.18e-07	2	23	2	33318558
Pubmed	Latent-Profile Analysis Reveals Behavioral and Brain Correlates of Dopamine-Cognition Associations.	DRD2 DRD3	4.18e-07	2	23	2	29028935
Pubmed	[123I]epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: implications for the use of cerebellum as a reference region.	DRD2 DRD3	4.18e-07	2	23	2	17175177
Pubmed	Activity, non-selective attention and emotionality in dopamine D2/D3 receptor knock-out mice.	DRD2 DRD3	4.18e-07	2	23	2	11864730
Pubmed	A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [(11)C](+)PHNO.	DRD2 DRD3	4.18e-07	2	23	2	26164205
Pubmed	Dopamine Receptor Signaling in MIN6 β-Cells Revealed by Fluorescence Fluctuation Spectroscopy.	DRD2 DRD3	4.18e-07	2	23	2	27508444
Pubmed	Dopamine D2 (DAD2) and dopamine D3 (DAD3) receptor gene polymorphisms and treatment outcome in alcohol dependence.	DRD2 DRD3	4.18e-07	2	23	2	12811641
Pubmed	Dopamine D2/D3 receptor stimulation fails to promote dopaminergic neurogenesis of murine and human midbrain-derived neural precursor cells in vitro.	DRD2 DRD3	4.18e-07	2	23	2	17784836
Pubmed	Positive association of dopamine D2 receptor polymorphism with bipolar affective disorder in a European Multicenter Association Study of affective disorders.	DRD2 DRD3	4.18e-07	2	23	2	11857579
Pubmed	Exploring regulation and function of dopamine D3 receptors in alcohol use disorder. A PET [11C]-(+)-PHNO study.	DRD2 DRD3	4.18e-07	2	23	2	34349232
Pubmed	Effects of smoking on D₂/D₃ striatal receptor availability in alcoholics and social drinkers.	DRD2 DRD3	4.18e-07	2	23	2	23649848
Pubmed	Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface.	DRD2 DRD3	4.18e-07	2	23	2	22291025
Pubmed	Chimeric D2/D3 dopamine receptors efficiently inhibit adenylyl cyclase in HEK 293 cells.	DRD2 DRD3	4.18e-07	2	23	2	8666994
Pubmed	Relationship of frontal D(2/3) binding potentials to cognition: a study of antipsychotic-naive schizophrenia patients.	DRD2 DRD3	4.18e-07	2	23	2	22338593
Pubmed	[¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.	DRD2 DRD3	4.18e-07	2	23	2	25641350
Pubmed	Postnatal ontogeny of dopamine D3 receptors in the mouse brain: autoradiographic evidence for a transient cortical expression.	DRD2 DRD3	4.18e-07	2	23	2	8836575
Pubmed	[11 C]raclopride positron emission tomography study of dopamine-D2/3 receptor binding in patients with severe major depressive episodes before and after electroconvulsive therapy and compared to control subjects.	DRD2 DRD3	4.18e-07	2	23	2	31943514
Pubmed	A shared spatial topography links the functional connectome correlates of cocaine use disorder and dopamine D2/3 receptor densities.	DRD2 DRD3	4.18e-07	2	23	2	39300138
Pubmed	Association Study Between DRD2, DRD3 Genetic Polymorphisms and Adverse Reactions in Chinese Patients on Amisulpride Treatment.	DRD2 DRD3	4.18e-07	2	23	2	39187246
Pubmed	Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.	DRD2 DRD3	4.18e-07	2	23	2	19217026
Pubmed	Examining the Effects of Sodium Ions on the Binding of Antagonists to Dopamine D2 and D3 Receptors.	DRD2 DRD3	4.18e-07	2	23	2	27379794
Pubmed	Dopamine D2/3 Binding Potential Modulates Neural Signatures of Working Memory in a Load-Dependent Fashion.	DRD2 DRD3	4.18e-07	2	23	2	30478031
Pubmed	Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis.	DRD2 DRD3	4.18e-07	2	23	2	22591910
Pubmed	Early expression of D3 dopamine receptors in murine embryonic development.	DRD2 DRD3	4.18e-07	2	23	2	8601467
Pubmed	Candidate gene analysis in an on-going genome-wide association study of attention-deficit hyperactivity disorder: suggestive association signals in ADRA1A.	DRD2 DRD3 ADRA2B	8.19e-07	28	23	3	19352218
Pubmed	Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum.	DRD2 DRD3	1.25e-06	3	23	2	18644790
Pubmed	The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice.	DRD2 DRD3	1.25e-06	3	23	2	10341260
Pubmed	Association of functional variants in the dopamine D2-like receptors with risk for gambling behaviour in healthy Caucasian subjects.	DRD2 DRD3	1.25e-06	3	23	2	20452395
Pubmed	Association of dopamine D(3) receptors with actin-binding protein 280 (ABP-280).	DRD2 DRD3	1.25e-06	3	23	2	11911837
Pubmed	Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: A systematic review and meta-analysis.	DRD2 DRD3	1.25e-06	3	23	2	30103286
Pubmed	Dopamine receptors and transporters in the brain reward circuits of type 1 and 2 alcoholics measured with human whole hemisphere autoradiography.	DRD2 DRD3	1.25e-06	3	23	2	12781734
Pubmed	Dopaminergic gene polymorphisms affect long-term forgetting in old age: further support for the magnification hypothesis.	DRD2 DRD3	1.25e-06	3	23	2	23363412
Pubmed	DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents.	DRD2 DRD3	1.25e-06	3	23	2	18351593
Pubmed	Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors.	DRD2 DRD3	1.25e-06	3	23	2	7566118
Pubmed	Association study of dopamine receptor genes polymorphisms with the risk of schizophrenia in the Han Chinese population.	DRD2 DRD3	1.25e-06	3	23	2	27591410
Pubmed	Enhancement of dopamine-induced signaling responses in the forebrain of mice lacking dopamine D3 receptor.	DRD2 DRD3	1.25e-06	3	23	2	15016423
Pubmed	Single nucleotide polymorphisms in genes of dopaminergic pathways are associated with bruxism.	DRD2 DRD3	1.25e-06	3	23	2	28451935
Pubmed	Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding.	DRD2 DRD3	1.25e-06	3	23	2	12210290
Pubmed	Prevalence of polymorphisms in the ANKK1, DRD2, DRD3 genes and metabolic syndrome in refractory schizophrenia.	DRD2 DRD3	1.25e-06	3	23	2	29791666
Pubmed	Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters.	DRD2 DRD3	1.25e-06	3	23	2	17942719
Pubmed	Targeted disruption of the dopamine D(2) and D(3) receptor genes leads to different alterations in the expression of striatal calbindin-D(28k).	DRD2 DRD3	1.25e-06	3	23	2	10828532
Pubmed	Dopamine D4 receptors elevated in schizophrenia.	DRD2 DRD3	1.25e-06	3	23	2	8413587
Pubmed	[Dopamine receptor gene polymorphisms in Guangzhou Hans].	DRD2 DRD3	1.25e-06	3	23	2	11024217
Pubmed	Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors.	DRD2 DRD3	1.25e-06	3	23	2	9354330
Pubmed	The mRNA Expression Status of Dopamine Receptor D2, Dopamine Receptor D3 and DARPP-32 in T Lymphocytes of Patients with Early Psychosis.	DRD2 DRD3	1.25e-06	3	23	2	26561806
Pubmed	Endosomal location of dopamine receptors in neuronal cell cytoplasm.	DRD2 DRD3	1.25e-06	3	23	2	17593530
Pubmed	Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease.	DRD2 DRD3	1.25e-06	3	23	2	29191473
Pubmed	Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors.	DRD2 DRD3	1.25e-06	3	23	2	17407504
Interaction	H4C12 interactions	SHPRH HAT1 HJURP	3.10e-05	54	23	3	int:H4C12
Interaction	H4C13 interactions	SHPRH HAT1 HJURP	3.85e-05	58	23	3	int:H4C13
Interaction	SMARCA1 interactions	SHPRH HAT1 TFPT HJURP	5.65e-05	188	23	4	int:SMARCA1
Interaction	H4C6 interactions	SHPRH HAT1 HJURP	6.48e-05	69	23	3	int:H4C6
Interaction	PWWP2A interactions	SHPRH HAT1 HJURP	8.65e-05	76	23	3	int:PWWP2A
Interaction	LIN37 interactions	SHPRH HAT1 HJURP	1.58e-04	93	23	3	int:LIN37
Cytoband	Ensembl 112 genes in cytogenetic band chr2q31	HAT1 PJVK	3.58e-03	178	23	2	chr2q31
Cytoband	Ensembl 112 genes in cytogenetic band chr17p13	LIAT1 NLGN2	1.29e-02	346	23	2	chr17p13
GeneFamily	Dopamine receptors	DRD2 DRD3	5.56e-06	5	14	2	181
Coexpression	GSE43955_TGFB_IL6_VS_TGFB_IL6_IL23_TH17_ACT_CD4_TCELL_52H_UP	TFPT DRD2 ADRA2B SCN9A	2.60e-05	200	23	4	M9667
Coexpression	GSE17721_POLYIC_VS_GARDIQUIMOD_2H_BMDC_UP	SHPRH PEX16 TFPT KANSL2	2.60e-05	200	23	4	M4018
CoexpressionAtlas	Embryoid Body Cells-reprogram_OSKM - NLT_vs_Embryoid Body Cells-reprogram_NA-Confounder_removed-fold2.0_adjp0.05	LIAT1 DRD2	6.72e-06	4	23	2	PCBC_ratio_EB_from-OSKM - NLT_vs_EB_from-ESC_cfr-2X-p05
ToppCell	LPS-antiTNF-Myeloid-Monocytes,_Macrophages-T-cells\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYO5A CHPF2 PJVK	4.58e-05	136	23	3	186be8e1595608004b8216892cb9c7a7f31fbb4d
ToppCell	facs-Marrow-B-cells-3m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	VWA3A PJVK SCN9A	4.68e-05	137	23	3	4dcb15de821439011df1bb0bbd7682d674bd725d
ToppCell	facs-Marrow-B-cells-3m-Myeloid-granulocyte\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	VWA3A PJVK SCN9A	4.68e-05	137	23	3	c05ceeb7b483324604cb3f647d2da2b3786071b1
ToppCell	PND01-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_mature\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A TFEC UNC93B1	7.70e-05	162	23	3	228e33678c7f963b3032a218333f206e5fff1292
ToppCell	PND01-Immune-Immune_Myeloid-Monocytic-Macrophage-IM\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A TFEC UNC93B1	8.13e-05	165	23	3	cece16b03282d27fb49102eb9c104a2024efd28c
ToppCell	PND10-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_mature\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A TFEC UNC93B1	9.19e-05	172	23	3	f0e767a20d93e546ce278db67dbd779cc68af533
ToppCell	E16.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A TFEC UNC93B1	9.19e-05	172	23	3	714172f31abd0d25261df6115ec6a9df491fa14b
ToppCell	renal_papilla_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_low-phase\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	PEX16 HJURP AP4B1	9.35e-05	173	23	3	506efcaa5afd6ed5e565c4c4def6a4505fea97c5
ToppCell	E16.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A TFEC UNC93B1	9.51e-05	174	23	3	0a8fa44604be19fbac722ebc6d1cd72b71be7022
ToppCell	PND10-Immune-Immune_Myeloid-Monocytic-Macrophage-IM\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A TFEC UNC93B1	9.51e-05	174	23	3	f520b79d277e286c9bb5d091e6c94e7ec7e46699
ToppCell	PND10-Immune-Immune_Myeloid-Monocytic-Macrophage\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A TFEC UNC93B1	9.67e-05	175	23	3	a8b05972e1bec4de73feaa6c4a9bcbe6b50c8044
ToppCell	Fetal_29-31_weeks-Immune-interstitial_macrophage_(C1Q_positive)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	MYO5A TFEC SCN9A	1.18e-04	187	23	3	39b99f46b723f7f3c44880d7fe8642cbad558b8a
ToppCell	COVID-19-Heart-Macrophage\|COVID-19 / Disease (COVID-19 only), tissue and cell type	MYO5A TFEC SCN9A	1.21e-04	189	23	3	2586f4088721c5debec86c2b211b739fd33713eb
ToppCell	HSPCs-Gran/Mono_prog.\|World / Lineage and Cell class	HAT1 TFEC UNC93B1	1.23e-04	190	23	3	94547c1cc2c3f2ac28a6d07317e50e1e3fd20267
ToppCell	LV-08._Macrophage\|World / Chamber and Cluster_Paper	MYO5A TFEC SCN9A	1.25e-04	191	23	3	e7a0bc46ba9ba772636a583f3387748418e18832
ToppCell	10x3'2.3-week_17-19-Myeloid_DC-DC-pDC\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	ADRA2B UNC93B1 SCN9A	1.25e-04	191	23	3	faf4de97003a938a243b0101456913c2b0e1804f
ToppCell	RV-08._Macrophage\|World / Chamber and Cluster_Paper	MYO5A TFEC SCN9A	1.27e-04	192	23	3	a1b5dc5beb97a23729b97b54fb4574d10d8fbfb3
ToppCell	LV-08._Macrophage\|LV / Chamber and Cluster_Paper	MYO5A TFEC SCN9A	1.27e-04	192	23	3	7be12d580aaf2f2f1562203fcad3a44639b8c5a6
ToppCell	Fetal_29-31_weeks-Immune-alveolar_macrophage_(MARCO_positive)-D150\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	MYO5A TFEC SCN9A	1.29e-04	193	23	3	2d0dd2671ff27b922eb316f1ed0140353536ef30
ToppCell	Immune-interstitial_macrophage_(C1Q_positive)\|World / Lineage, Cell type, age group and donor	MYO5A TFEC SCN9A	1.29e-04	193	23	3	64d598162a256ac6c9f8280c8a9133661dfbb10f
ToppCell	RV-08._Macrophage\|RV / Chamber and Cluster_Paper	MYO5A TFEC SCN9A	1.29e-04	193	23	3	12bf98a280f87e4d8f0c6887dfc855da72e47ac1
ToppCell	356C-Myeloid-Macrophage\|356C / Donor, Lineage, Cell class and subclass (all cells)	TFEC TFPT UNC93B1	1.31e-04	194	23	3	3844e6fb43ae2e0a35ea8ccc1a2e11f40b68bc67
ToppCell	COVID-19-Heart-Macrophage\|Heart / Disease (COVID-19 only), tissue and cell type	MYO5A TFEC SCN9A	1.31e-04	194	23	3	f09675cd472200363c458952f00d2e41990800ee
ToppCell	LA-08._Macrophage\|World / Chamber and Cluster_Paper	MYO5A TFEC SCN9A	1.31e-04	194	23	3	c1805572bcc11b1cd29083329d7b5911489fb758
ToppCell	COVID-19-Lymphoid-pDC\|Lymphoid / Condition, Lineage and Cell class	TFEC UNC93B1 SCN9A	1.33e-04	195	23	3	4a7c080230ce6a79335ecbeadecb0177b2c13625
ToppCell	LA-08._Macrophage\|LA / Chamber and Cluster_Paper	MYO5A TFEC SCN9A	1.33e-04	195	23	3	5e1d5bdb8874091f5a2b1d0a8cc9008165718a97
ToppCell	control-CD163+_Monocytes_(Sample_ID1_d7)\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	JAK2 TFEC UNC93B1	1.33e-04	195	23	3	19413dc6aa0010686cdfa0c750ef0a7a76caf308
ToppCell	Bronchial-NucSeq-Immune_Myeloid-Macrophage_other-Macrophage_intravascular\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	MYO5A TFEC SCN9A	1.39e-04	198	23	3	c7dbf24caae5c4ef285845d13055de9e07281bb3
ToppCell	control-HLA-DR+_CD83+_Monocyte\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	JAK2 TFEC UNC93B1	1.39e-04	198	23	3	35499a5231818e3432cf69b5c4a58c02f7771db8
ToppCell	PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Myeloid-Monocytic-Classical_Monocyte-Mono_c2-CD14-HLA-DPB1\|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)	JAK2 TFEC UNC93B1	1.41e-04	199	23	3	4fc03377c017209111561789226621d258291481
ToppCell	wk_20-22-Hematologic-Myeloid-SPP1+_Mac\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	MYO5A TFEC SCN9A	1.41e-04	199	23	3	7c19f1b1f4369edd035ca9cdcf4e653771fc4648
ToppCell	control-CD163+_Monocytes_(Sample_ID1_d7)\|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	JAK2 TFEC UNC93B1	1.41e-04	199	23	3	933201d32eda12a89660bdbae9114a95cc428a38
ToppCell	BAL-Mild-cDC_1\|Mild / Compartment, Disease Groups and Clusters	JAK2 TFEC UNC93B1	1.41e-04	199	23	3	c55181bdec8952b54198f0d4c9c5c84265b16572
ToppCell	control-HLA-DR+_CD83+_Monocyte\|control / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	JAK2 TFEC UNC93B1	1.41e-04	199	23	3	f1b370d2869ad29c9d8ff41fdcc486fffa781ee2
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW08-Mesenchymal\|GW08 / Sample Type, Dataset, Time_group, and Cell type.	JAK2 TFEC DRD2	1.44e-04	200	23	3	e5b7d9622b96bb20c81ac76b4e60e8b44fa9cca1
ToppCell	Substantia_nigra-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a6-Excitatory_Neuron.Slc17a6.Nts_(peripeduncular_nucleus_&_posterior_intralaminar_thalamic_nucleus_(PP_&_PIL))\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	PJVK ADRA2B	5.26e-04	66	23	2	6cf03dd1db7607684cdcca7df08933f8cdc3adef
ToppCell	Substantia_nigra-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Slc17a6-Excitatory_Neuron.Slc17a6.Nts_(peripeduncular_nucleus_&_posterior_intralaminar_thalamic_nucleus_(PP_&_PIL))-\|Substantia_nigra / BrainAtlas - Mouse McCarroll V32	PJVK ADRA2B	5.26e-04	66	23	2	85e0027bf0d4ebdcb6cac358aedd1d74aa83c612
ToppCell	TCGA-Brain-Recurrent_Tumor-Low_Grade_Glioma-Oligodendroglioma-6\|TCGA-Brain / Sample_Type by Project: Shred V9	TFPT IMP4	1.64e-03	117	23	2	cf458fe514c570c22001085733ca12fb5cf58ee8
ToppCell	Posterior_cortex-Neuronal-Excitatory-eN1(Slc17a7)-eN1_1-Calb1\|Posterior_cortex / BrainAtlas - Mouse McCarroll V32	VWA3A LIAT1	1.72e-03	120	23	2	a6d0406a174d46ce06b41280292931954af88a59
ToppCell	primary_visual_cortex-Non-neuronal-macrophage-Macrophage-PVM_Mrc1\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TFEC UNC93B1	2.01e-03	130	23	2	3a0846b74ba34bd0e2a05b4f1f39f3940df93780
ToppCell	Hippocampus-Macroglia-POLYDENDROCYTE-P5-P5_1-Sox4-POLYDENDROCYTE_(Neurogenesis.Sox4.Cdc20)\|Hippocampus / BrainAtlas - Mouse McCarroll V32	DRD3 PJVK	2.04e-03	131	23	2	f9fb8d74ca720b81fd5910cc975510359a8ef751
ToppCell	PND01-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A UNC93B1	2.40e-03	142	23	2	be63c48794a227ea55978524c0f5935342fc455e
ToppCell	facs-Trachea-18m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l20-23\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	DRD3 SCN9A	2.46e-03	144	23	2	e9d62f202f0fa8747961036ef0eafed91fe8a42f
ToppCell	metastatic_Brain-T/NK_cells-Naive_CD8+_T\|T/NK_cells / Location, Cell class and cell subclass	PEX16 ADRA2B	2.56e-03	147	23	2	4f7a0c287721befeffabf95b8c5f9ff64149c7c1
ToppCell	frontal_cortex-Non-neuronal-macrophage-Macrophage-PVM_Mrc1\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	TFEC UNC93B1	2.60e-03	148	23	2	d3ea907f8f408e9bb97ed223a3089e403e35f911
ToppCell	renal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_low-phase\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	VWA3A HJURP	2.63e-03	149	23	2	a6406c4c9404271a2f4c615c6cd3265b2d759b12
ToppCell	E16.5-samps-Myeloid-Fetal_macrophage-macrophage_-_intermediate_-_unactivated\|E16.5-samps / Age Group, Lineage, Cell class and subclass	TFEC UNC93B1	2.67e-03	150	23	2	60fdd266aaca1b589b9a77465a4a7fad4921339a
ToppCell	normal_Lung-Myeloid_cells-Undetermined\|normal_Lung / Location, Cell class and cell subclass	ADRA2B SCN9A	2.70e-03	151	23	2	23b6cf9a36ad0e937f69c75921bddd305a9a526c
ToppCell	LPS-antiTNF-Epithelial_alveolar-Mes-Like-AT2_Progenitor\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	VWA3A HJURP	2.70e-03	151	23	2	c06a54afe918b14f885d6a85fbcf81e80f33afae
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic-Neutrophil-Neu_c6-FGF23\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	MYO5A SCN9A	2.74e-03	152	23	2	0652ee3443e6fbb679d2c4f326239ae7c803f924
ToppCell	PND10-Immune-Immune_Myeloid-DC-cDC2\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A JAK2	2.74e-03	152	23	2	27718e92715ddc80f28b457a5d6d6a3ac2b205d2
ToppCell	facs-Trachea-24m-Hematologic-myeloid-tracheal_macrophage-macrophage_of_trachea\|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TFEC UNC93B1	2.74e-03	152	23	2	931c10245cde9b3290224cc1da46b2bf300b9ac2
ToppCell	E16.5-samps-Myeloid-Fetal_macrophage-Proliferative_Myeloid\|E16.5-samps / Age Group, Lineage, Cell class and subclass	TFEC UNC93B1	2.74e-03	152	23	2	e427758a6e39052616a0d8ecec0c1299e81d1d3c
ToppCell	E16.5-samps-Myeloid-Fetal_macrophage\|E16.5-samps / Age Group, Lineage, Cell class and subclass	TFEC UNC93B1	2.77e-03	153	23	2	e9567966fe4426176e2f2dc0be4832c769c9903a
ToppCell	E18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_prolif\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A UNC93B1	2.81e-03	154	23	2	79ebda35dd1719e157738d7c13e5b8ccc3991f03
ToppCell	frontal_cortex-Neuronal-glutamatergic_neuron-L5_IT-L5_IT_ALM_Tnc\|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	VWA3A LIAT1	2.81e-03	154	23	2	0066b2b8cfc74603e97f271ef5efc7ec512110dc
ToppCell	droplet-Liver-Npc-21m-Myeloid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PJVK UNC93B1	2.81e-03	154	23	2	d883b3e2a65e4375bea1216eb9bbc86c64ee449c
ToppCell	PND03-Immune-Immune_Myeloid-DC-cDC2\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A UNC93B1	2.81e-03	154	23	2	c663e9834be0b45389a862dc3c13a1f988a3e5ee
ToppCell	droplet-Liver-LIVER_HEPATOCYTES-30m-Myeloid\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYO5A LIAT1	2.81e-03	154	23	2	1e32969bee810adaf2d560f0824a16227df513d8
ToppCell	droplet-Liver-Npc-21m-Myeloid-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PJVK UNC93B1	2.85e-03	155	23	2	5d600e159738231d0607ea1a1ebd8510fc241b36
ToppCell	343B-Lymphocytic-NK_cells-NK_cell_B0\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	NLGN2 SCN9A	2.85e-03	155	23	2	583cfaa41c755c63aee312eb442e9d97f645d5f7
ToppCell	PND07-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_prolif\|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TFEC UNC93B1	2.85e-03	155	23	2	93bfcf5c12cbb61a1e0444312afd2aa411a8bf50
ToppCell	343B-Myeloid-Macrophage-SPP1+_Macrophage_2\|343B / Donor, Lineage, Cell class and subclass (all cells)	TFEC ADRA2B	2.85e-03	155	23	2	84221a285277292f7225eb69508c887541abeed1
ToppCell	5'-GW_trimst-1-SmallIntestine-Mesenchymal-immature_mesenchymal_cell-Mesoderm_2_(ZEB2+)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	JAK2 AP4B1	2.88e-03	156	23	2	d411116d54add2d4fe649a97ac54cb94c085312f
ToppCell	10x5'v1-week_12-13-Myeloid_DC-DC-DC2\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	JAK2 PJVK	2.88e-03	156	23	2	03f3c5ffb27758fe63797143fcc938f9e8a4e10d
ToppCell	E16.5-samps-Myeloid\|E16.5-samps / Age Group, Lineage, Cell class and subclass	TFEC UNC93B1	2.88e-03	156	23	2	c7c73cef5700b0ae75280e62c94728434c712537
ToppCell	PND03-Immune-Immune_Myeloid-Monocytic-Macrophage-iMON-iMON_prolif\|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	HAT1 UNC93B1	2.92e-03	157	23	2	eea53cf8d8a607264e1ee00b7a97c94bcf2ac80d
ToppCell	E15.5-Hematopoietic-Immune-immune_cell_unspecified\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	2.92e-03	157	23	2	4263627911657e788a1d0230690ee434e8a4f9a1
ToppCell	E12.5-Hematopoietic\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	2.92e-03	157	23	2	344351c7534440532c6cd4a95782ac90b10d45f3
ToppCell	E15.5-Hematopoietic-Immune\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	2.92e-03	157	23	2	de689a133863ed74d848eba0a4f392357ac28245
ToppCell	E15.5-Hematopoietic\|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	2.92e-03	157	23	2	6315aef4b9bf673069d43a730d4e940011509ac1
ToppCell	droplet-Bladder-Unstain-18m-Hematologic-macrophage\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TFEC UNC93B1	2.95e-03	158	23	2	e5e7b2d609973f1dd4fe7dc62bb69422268ea801
ToppCell	Control-Hematopoietic_Meg-Ery-Platelets-Platelets\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	VWA3A HJURP	2.95e-03	158	23	2	f2c39b2eff8f2728a9d482d88e0d04984306a3fd
ToppCell	Control-Hematopoietic_Meg-Ery-Platelets\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	VWA3A HJURP	2.95e-03	158	23	2	fa9797a23254070c569fabe8a314b3e8b3ae9ebd
ToppCell	E17.5-Hematopoietic\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	2.99e-03	159	23	2	a5648f731f1a22d1af1be2b0e1b80e29d05bae04
ToppCell	E16.5-Immune-Immune_Myeloid-Monocytic-Macrophage-iMON-iMON_mature\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TFEC UNC93B1	2.99e-03	159	23	2	dd9059f98eec43adbcc0cd42bb155670f7a3a479
ToppCell	E12.5-Hematopoietic-Immune\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	3.03e-03	160	23	2	cd59830a524c14a1f591c5c615b55510e4104e5b
ToppCell	E16.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_prolif\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A UNC93B1	3.03e-03	160	23	2	18954241e11309ecb0f3ca87897eadcb20dc8eca
ToppCell	facs-Trachea-nan-18m-Myeloid-lymphocyte_of_B_lineage\|Trachea / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PEX16 UNC93B1	3.03e-03	160	23	2	5c9281706009558c8361bfa76169f43ffc0f7947
ToppCell	droplet-Lung-nan-21m-Myeloid-intermediate_monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	JAK2 UNC93B1	3.03e-03	160	23	2	4738d0c73d8c3508e5b5beb6c61e0ad551d9b949
ToppCell	E12.5-Hematopoietic-Immune-immune_cell_unspecified\|E12.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	3.03e-03	160	23	2	5a4a5a50dfdf6af9406e4f685712f7fe390a02f3
ToppCell	droplet-Lung-nan-21m-Myeloid-Intermediate_Monocyte\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	JAK2 UNC93B1	3.03e-03	160	23	2	0b8151037b28f52a21918856a1e9336e8d5edb90
ToppCell	droplet-Liver-Npc-21m-Myeloid-Kupffer_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PJVK UNC93B1	3.03e-03	160	23	2	85205dc68369d3e04df3460c1f3861ee2dc242a9
ToppCell	facs-Liver-Non-hepatocytes-3m-Myeloid-myeloid_leukocyte\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MYO5A LIAT1	3.03e-03	160	23	2	237430af14830b38e58da8a4224036e5c6b71c5b
ToppCell	PND28-Immune-Immune_Myeloid-DC-cDC1-cDC1_mature\|PND28 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	JAK2 PJVK	3.06e-03	161	23	2	76c993a4533362db2250c88b3ee3ede55362d54e
ToppCell	E17.5-Hematopoietic-Immune\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	3.06e-03	161	23	2	e3ff08d0b9c686253556c56ee88648206751ef2b
ToppCell	normal_Lung-Myeloid_cells-Undetermined\|Myeloid_cells / Location, Cell class and cell subclass	VWA3A SCN9A	3.06e-03	161	23	2	283012858e575c70d09950de53da041509f59bfa
ToppCell	PND10-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_prolif\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TFEC UNC93B1	3.06e-03	161	23	2	8937f6b92cb2a93ea8c4780d9200a518c3112e53
ToppCell	E17.5-Hematopoietic-Immune-immune_cell_unspecified\|E17.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase	TFEC UNC93B1	3.06e-03	161	23	2	30741ca6548db2dfb5cf1faecf0d7412c91d0077
ToppCell	E18.5-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_G2M\|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A UNC93B1	3.10e-03	162	23	2	ec29c6f1c31e41ddcb041a49c593910edaf0532c
ToppCell	Control-Epithelial-Ionocyte\|World / Disease state, Lineage and Cell class	ADRA2B SCN9A	3.10e-03	162	23	2	e3b9b46ce2faff7d099502df14bbf51e9f183f8c
ToppCell	Control-Epithelial-Ionocyte\|Control / Disease state, Lineage and Cell class	ADRA2B SCN9A	3.14e-03	163	23	2	bf09fa39bf3e6b3a776d5e79c30c96df572956a3
ToppCell	368C-Myeloid-Macrophage-M2-like_Macrophage_(MARCO_negative)\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	MYO5A SCN9A	3.14e-03	163	23	2	4b8abbad4df040c895e3afb240759ebbc66b4d0e
ToppCell	PND01-Immune\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TFEC UNC93B1	3.14e-03	163	23	2	98af13bd4257a9da325e1ffe5a254f0f58ca6c4b
ToppCell	facs-MAT-Fat-3m-Myeloid-myeloid_cell\|MAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TFEC UNC93B1	3.14e-03	163	23	2	5fc836444bc156c8248abee001b0ecbe43f980c9
ToppCell	PND10-Immune-Immune_Myeloid-DC-cDC2-cDC2_prolif\|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	MYO5A JAK2	3.14e-03	163	23	2	7af3d3ae7e0de733a18d0486c7ffbb5a7ef7230a
ToppCell	E16.5-Immune-Immune_Myeloid-Monocytic-Macrophage-iMON\|E16.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TFEC UNC93B1	3.14e-03	163	23	2	45a0a03d642a9751f522b2f068598ab5de4a87bd
ToppCell	PND01-Immune-Immune_Myeloid\|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif	TFEC UNC93B1	3.14e-03	163	23	2	ca12d01615be371fe215ec673d4ec787381e0ca6
ToppCell	droplet-Lung-21m-Hematologic-myeloid-intermediate_monocyte-intermediate_monocyte_l4\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	JAK2 UNC93B1	3.18e-03	164	23	2	12251a49fd4af32d4edb58046245548c260cf04b
ToppCell	droplet-Heart-nan-3m-Hematologic\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TFEC UNC93B1	3.18e-03	164	23	2	df9fe446c1a43100048e11c01bf009bec3414dcf
Drug	Yohimbine	DRD2 DRD3 ADRA2B	1.08e-07	10	23	3	DB01392
Drug	dihydroergocryptine	JAK2 DRD2 DRD3 ADRA2B	1.63e-07	49	23	4	CID000114948
Drug	Lisuride	DRD2 DRD3 ADRA2B	3.25e-07	14	23	3	DB00589
Drug	epidepride	DRD2 DRD3 ADRA2B	3.25e-07	14	23	3	CID000086101
Drug	Pramipexole	DRD2 DRD3 ADRA2B	3.25e-07	14	23	3	DB00413
Drug	Ropinirole	DRD2 DRD3 ADRA2B	3.25e-07	14	23	3	DB00268
Drug	Risperidone	DRD2 DRD3 ADRA2B	3.25e-07	14	23	3	DB00734
Drug	Cabergoline	DRD2 DRD3 ADRA2B	4.06e-07	15	23	3	DB00248
Drug	Apomorphine	DRD2 DRD3 ADRA2B	4.06e-07	15	23	3	DB00714
Drug	Paliperidone	DRD2 DRD3 ADRA2B	6.07e-07	17	23	3	DB01267
Drug	Pergolide	DRD2 DRD3 ADRA2B	6.07e-07	17	23	3	DB01186
Drug	Bromocriptine	DRD2 DRD3 ADRA2B	7.28e-07	18	23	3	DB01200
Drug	Ro 41-9067	DRD2 DRD3 ADRA2B	8.63e-07	19	23	3	CID000125800
Drug	Methotrimeprazine	DRD2 DRD3 ADRA2B	8.63e-07	19	23	3	DB01403
Drug	3-(3-cyanophenyl)-N-n-propylpiperidine	DRD2 DRD3	9.76e-07	2	23	2	ctd:C094012
Drug	iodosulpride	DRD2 DRD3	9.76e-07	2	23	2	ctd:C045105
Drug	UH 232	DRD2 DRD3	9.76e-07	2	23	2	ctd:C045971
Drug	GR 218231	DRD2 DRD3	9.76e-07	2	23	2	ctd:C408390
Drug	Sulpiride	DRD2 DRD3	9.76e-07	2	23	2	DB00391
Drug	fluoroclebopride	DRD2 DRD3	9.76e-07	2	23	2	ctd:C083673
Drug	4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrzolo(3,4-g)quinoline	DRD2 DRD3	9.76e-07	2	23	2	ctd:C416545
Drug	N-n-propyl-N-phenylethyl-4(3-hydroxyphenyl)ethylamine hydrochloride	DRD2 DRD3	9.76e-07	2	23	2	ctd:C016868
Drug	5-methoxy-1-methyl-2-(n-propylamino)tetralin	DRD2 DRD3	9.76e-07	2	23	2	ctd:C051171
Drug	N-(4-(2-(4-(3-cyano-5-trifluoromethylphenyl)piperazin-1-yl)ethyl)cyclohexyl)-3-pyridinesulfonic amide	DRD2 DRD3	9.76e-07	2	23	2	ctd:C539157
Drug	CGS 15855A	DRD2 DRD3	9.76e-07	2	23	2	ctd:C051347
Drug	Piribedil	DRD2 DRD3	9.76e-07	2	23	2	ctd:D010891
Drug	AC1L31N6	DRD2 DRD3	9.76e-07	2	23	2	CID000132830
Drug	(5,6-dimethoxyindan-2-yl)dipropylamine	DRD2 DRD3	9.76e-07	2	23	2	ctd:C086335
Drug	Domperidone	DRD2 DRD3	9.76e-07	2	23	2	DB01184
Drug	droperidol	DRD2 DRD3 ADRA2B	1.57e-06	23	23	3	CID000003168
Drug	ibopamine	DRD2 DRD3 ADRA2B	1.80e-06	24	23	3	CID000068555
Drug	epinine	DRD2 DRD3 ADRA2B	1.80e-06	24	23	3	CID000004382
Drug	Olanzapine	DRD2 DRD3 ADRA2B	2.04e-06	25	23	3	DB00334
Drug	Ziprasidone	DRD2 DRD3 ADRA2B	2.04e-06	25	23	3	DB00246
Drug	Aripiprazole	DRD2 DRD3 ADRA2B	2.04e-06	25	23	3	DB01238
Drug	fluphenazine	DRD2 DRD3 ADRA2B SCN9A	2.27e-06	94	23	4	CID000003372
Drug	T15550	DRD2 DRD3 ADRA2B	2.31e-06	26	23	3	CID000005454
Drug	FLA-63	DRD2 DRD3 ADRA2B	2.31e-06	26	23	3	CID000033295
Drug	Clozapine	DRD2 DRD3 ADRA2B	2.31e-06	26	23	3	DB00363
Drug	Quetiapine	DRD2 DRD3 ADRA2B	2.31e-06	26	23	3	DB01224
Drug	NSC169490	DRD2 DRD3 ADRA2B	2.59e-06	27	23	3	CID004210613
Drug	L-741,626	DRD2 DRD3 ADRA2B	2.90e-06	28	23	3	CID000133633
Drug	roxindole	DRD2 DRD3 ADRA2B	2.90e-06	28	23	3	CID000219050
Drug	(1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-hydroxy-3-phenylpropyl) piperazinyl decanoate)	DRD2 DRD3	2.93e-06	3	23	2	ctd:C461261
Drug	DP-6OH-3CA	DRD2 DRD3	2.93e-06	3	23	2	CID000086146
Drug	7-hydroxy-2-N,N-dipropylaminotetralin	DRD2 DRD3	2.93e-06	3	23	2	ctd:C031349
Drug	quinelorane	DRD2 DRD3	2.93e-06	3	23	2	ctd:C047726
Drug	Neuriplege	DRD2 DRD3	2.93e-06	3	23	2	CID000065750
Drug	nafadotride	DRD2 DRD3	2.93e-06	3	23	2	ctd:C097285
Drug	FLA908	DRD2 DRD3	2.93e-06	3	23	2	CID000129516
Drug	SB-277011	DRD2 DRD3	2.93e-06	3	23	2	CID005311096
Drug	7-(N,N-dipropylamino)-5,6,7,8-tetrahydronaphtho(2,3-b)dihydro-2,3-furan	DRD2 DRD3	2.93e-06	3	23	2	ctd:C090812
Drug	DCHAPS	DRD2 DRD3	2.93e-06	3	23	2	CID000129392
Drug	BP 897	DRD2 DRD3	2.93e-06	3	23	2	ctd:C120565
Drug	iodoethylspiperone	DRD2 DRD3	2.93e-06	3	23	2	CID000131222
Drug	3-N-methylspiperone	DRD2 DRD3	2.93e-06	3	23	2	ctd:C039167
Drug	AC1L1G8Z	DRD2 DRD3 ADRA2B	3.59e-06	30	23	3	CID000003581
Drug	dopexamine	DRD2 DRD3 ADRA2B	4.38e-06	32	23	3	CID000055483
Drug	ropinirole	DRD2 DRD3 ADRA2B	4.82e-06	33	23	3	CID000005095
Drug	DB921	DRD2 DRD3 ADRA2B	4.82e-06	33	23	3	CID005327049
Drug	transdihydrolisuride	DRD2 DRD3 ADRA2B	5.28e-06	34	23	3	CID000005406
Drug	fluspirilene	DRD2 DRD3 ADRA2B	5.28e-06	34	23	3	CID000003396
Drug	3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol	DRD2 DRD3	5.85e-06	4	23	2	ctd:C062458
Drug	NCQ-469	DRD2 DRD3	5.85e-06	4	23	2	CID000127915
Drug	SKF83959	DRD2 DRD3	5.85e-06	4	23	2	CID000133538
Drug	spectramide	DRD2 DRD3	5.85e-06	4	23	2	CID000130377
Drug	Amisulpride	DRD2 DRD3	5.85e-06	4	23	2	DB06288
Drug	sarizotan	DRD2 DRD3	5.85e-06	4	23	2	ctd:C443959
Drug	clofluperol	DRD2 DRD3	5.85e-06	4	23	2	CID000025293
Drug	Pimozide	DRD2 DRD3	5.85e-06	4	23	2	DB01100
Drug	molindone	DRD2 DRD3 ADRA2B	6.29e-06	36	23	3	CID000023897
Drug	AC1MHW5N	DRD2 DRD3 ADRA2B	6.29e-06	36	23	3	CID003058747
Drug	iloperidone	DRD2 DRD3 ADRA2B	6.29e-06	36	23	3	CID000071360
Drug	Calcium	MYO5A JAK2 DRD2 DRD3 ADRA2B SCN9A	7.38e-06	493	23	6	ctd:D002118
Drug	rotigotine transdermal patch	DRD2 DRD3 ADRA2B	7.42e-06	38	23	3	CID000057537
Drug	pipamperone	DRD2 DRD3 ADRA2B	7.42e-06	38	23	3	CID000004830
Drug	NSC95090	DRD2 DRD3 ADRA2B	8.68e-06	40	23	3	CID000003251
Drug	FR 4	TFPT DRD2 DRD3	8.68e-06	40	23	3	CID005288243
Drug	Saphris	DRD2 DRD3 ADRA2B	9.36e-06	41	23	3	CID000163091
Drug	Haloperidol	DRD2 DRD3	9.74e-06	5	23	2	DB00502
Drug	SKF85174	DRD2 DRD3	9.74e-06	5	23	2	CID000132435
Drug	pipotiazine	DRD2 DRD3	9.74e-06	5	23	2	CID000062867
Drug	Remoxipride	DRD2 DRD3	9.74e-06	5	23	2	DB00409
Drug	moperone	DRD2 DRD3	9.74e-06	5	23	2	CID000004249
Drug	tilozepine	DRD2 DRD3	9.74e-06	5	23	2	CID000172286
Drug	2-di-n-propylaminoindan	DRD2 DRD3	9.74e-06	5	23	2	CID000130402
Drug	3-iodobenzamide	DRD2 DRD3	9.74e-06	5	23	2	CID000202425
Drug	dazopride	DRD2 DRD3	9.74e-06	5	23	2	CID000054801
Drug	haloperidol hemisuccinate	DRD2 DRD3	9.74e-06	5	23	2	CID000088143
Drug	declopramide	DRD2 DRD3	9.74e-06	5	23	2	CID000070177
Drug	mezilamine	DRD2 DRD3	9.74e-06	5	23	2	CID000068678
Drug	SKF 77434	DRD2 DRD3	9.74e-06	5	23	2	CID000001241
Drug	NO 756	DRD2 DRD3	9.74e-06	5	23	2	CID000129967
Drug	Levodopa	DRD2 DRD3	9.74e-06	5	23	2	DB01235
Drug	tefludazine	DRD2 DRD3	9.74e-06	5	23	2	CID000071240
Drug	azapride	DRD2 DRD3	9.74e-06	5	23	2	CID003036441
Drug	rotigotine	DRD2 DRD3	9.74e-06	5	23	2	ctd:C047508
Drug	piquindone	DRD2 DRD3	9.74e-06	5	23	2	CID000121903
Drug	piribedil	DRD2 DRD3 ADRA2B	1.01e-05	42	23	3	CID000004850
Drug	amitriptyline	DRD2 DRD3 ADRA2B SCN9A	1.11e-05	140	23	4	CID000002160
Disease	Disruptive, Impulse Control, and Conduct Disorders	DRD2 DRD3	1.74e-06	3	23	2	C0021122
Disease	Intermittent Explosive Disorder	DRD2 DRD3	1.74e-06	3	23	2	C0021776
Disease	heroin dependence (biomarker_via_orthology)	DRD2 DRD3	5.80e-06	5	23	2	DOID:9976 (biomarker_via_orthology)
Disease	Recurrent depression	DRD2 DRD3	2.09e-05	9	23	2	C0221480
Disease	Delirium	DRD2 DRD3	2.61e-05	10	23	2	C0011206
Disease	Lenticulostriate Disorders	DRD2 DRD3	3.82e-05	12	23	2	C0750951
Disease	Basal Ganglia Diseases	DRD2 DRD3	3.82e-05	12	23	2	C0004782
Disease	Extrapyramidal Disorders	DRD2 DRD3	3.82e-05	12	23	2	C0015371
Disease	nicotine dependence (implicated_via_orthology)	DRD2 DRD3	3.82e-05	12	23	2	DOID:0050742 (implicated_via_orthology)
Disease	Dyskinesia, Drug-Induced	DRD2 DRD3	6.06e-05	15	23	2	C0013386
Disease	Dyskinesia, Medication-Induced	DRD2 DRD3	6.06e-05	15	23	2	C0751088
Disease	Etat Marbre	DRD2 DRD3	1.46e-04	23	23	2	C0266487
Disease	Movement Disorders	DRD2 DRD3	2.33e-04	29	23	2	C0026650
Disease	Parkinsonism (implicated_via_orthology)	DRD2 DRD3	2.33e-04	29	23	2	DOID:0080855 (implicated_via_orthology)
Disease	Hyperkinesia, Generalized	DRD2 DRD3	2.84e-04	32	23	2	C0751217
Disease	Hyperkinesia	DRD2 DRD3	2.84e-04	32	23	2	C3887506
Disease	Cognition Disorders	DRD2 DRD3	4.02e-04	38	23	2	C0009241
Disease	attention deficit hyperactivity disorder, bipolar disorder, autism spectrum disorder, schizophrenia, major depressive disorder	DRD2 NCOA5	7.24e-04	51	23	2	EFO_0003756, EFO_0003888, MONDO_0002009, MONDO_0004985, MONDO_0005090
Disease	Alcohol abuse	DRD2 DRD3	1.25e-03	67	23	2	C0085762
Disease	Amphetamine Abuse	DRD2 DRD3	1.56e-03	75	23	2	C0236807
Disease	Amphetamine Addiction	DRD2 DRD3	1.56e-03	75	23	2	C0236804
Disease	Amphetamine-Related Disorders	DRD2 DRD3	1.56e-03	75	23	2	C0236733
Disease	obesity (is_implicated_in)	DRD2 ADRA2B	2.28e-03	91	23	2	DOID:9970 (is_implicated_in)

Protein segments in the cluster

Peptide	Gene	Start	Entry
RLRYRNVIQRVIRYM	AP4B1	26	Q9Y6B7
VYLRIYLIAKRSNRR	ADRA2B	191	P18089
RRRFQRRMQRLIEKY	HJURP	26	Q8NCD3
ARLRREYLYRKAREE	IMP4	6	Q96G21
RKRIRYRFRRFIQQF	JAK2	226	O60674
KREERRREELYRQYF	NCOA5	171	Q9HCD5
EQYRSYRLDIKRRLI	HAT1	346	O14929
KRLKCLRRYRQRYGV	KANSL2	256	Q9H9L4
LLVYIKIYIVLRRRR	DRD2	206	P14416
ALYYKRDRRQELRCR	NLGN2	696	Q8NFZ4
LVYARIYVVLKQRRR	DRD3	206	P35462
RRELRRRTILLLYYL	PEX16	271	Q9Y5Y5
IRIYKLNRRKRYRCL	LIAT1	186	Q6ZQX7
IQRAYRRYRLRQNVK	SCN9A	1896	Q15858
IYRYDVQRNRSLLKR	SHPRH	471	Q149N8
RLRFQKQRLLNGYRR	CHPF2	421	Q9P2E5
RYYRRKRLGVLKNVL	UNC93B1	51	Q9H1C4
RRRQRELNRRKYQAL	TFPT	71	P0C1Z6
YRLRNILFERNRRVM	PJVK	246	Q0ZLH3
YRLRKAERKRLRYAQ	SOGA3	411	Q5TF21
YRERLFRNQKILREY	SLC30A9	201	Q6PML9
LIERRRRYNINYRIK	TFEC	146	O14948
YIRHLEKVLRRYVQR	VWA3A	926	A6NCI4
RMYVVRRRYKIRRAA	MYO5A	826	Q9Y4I1